8 results about "Apelin" patented technology

The invention discloses a biomarker combination for predicting PCI postoperative LVR of an STEMI patient and application of the biomarker combination, and belongs to the technical field of biology. The research discovers that in a left ventricular remodeling (LVR) group and a non-left ventricular remodeling group after percutaneous coronary intervention (PCI) of a patient suffering from acute ST segment elevation type myocardial infarction (STEMI), a left ventricular endocardial lower myocardial overall longitudinal strain (GLS internal) value, a lung B-line integral, a serum sFRP5 level and Apelin-13 show significant differences. Through combined prediction analysis, it is found that the GLS internal value, the lung B-line integral, the serum sFRP5 and the Apelin-13 have excellent prediction performance on whether the LVR occurs after the PCI operation of the STEMI patient or not, high-risk groups, suffering from the LVR after the PCI operation, of the STEMI patient can be accurately and efficiently recognized, intervention is conducted as soon as possible, and the life quality of the patient is expected to be improved.

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and / or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

The invention provides an Apelin and HBD3 delivery system based on hydrogel and engineering extracellular vesicles as well as a preparation method and application of the Apelin and HBD3 delivery system, and belongs to the technical field of medicines. The preparation method comprises the following steps: transducing Wharton jelly-derived mesenchymal stem cells by utilizing a lentiviral vector, so that the Wharton jelly-derived mesenchymal stem cells are over-expressed with Apelin and HBD3 proteins, then extracting engineered EVs, and loading the engineered EVs in GelMA hydrogel, so as to obtain Apelin-HBD3-EVs-coated GelMA. According to the Apelin-HBD3-EVs (at) GelMA compound, the anti-inflammatory and antibacterial characteristics of the Apelin-HBD3-EVs (at) GelMA are verified through in-vitro experiments and in-vivo experiments, and the Apelin-HBD3-EVs (at) GelMA compound shows excellent anti-inflammatory, antibacterial and wound healing promoting effects in an old mouse infectious wound model, and shows huge application prospects for coping with special challenges of chronic wound treatment of old people.

The present invention aims to provide a novel component involved in angiogenesis, and a preventive and / or therapeutic agent for neurodegenerative diseases, demyelinating diseases, or cerebrovascular diseases using the same. [Solution] The apelin expression promoter of the present invention is an apelin expression promoter in vascular endothelial cells comprising one or more selected from the group consisting of mesenchymal stem cells, culture supernatant of mesenchymal stem cells, and cellular secretions of mesenchymal stem cells. The preventive and / or therapeutic agent of the present invention is a preventive and / or therapeutic agent for neurodegenerative diseases, demyelinating diseases, or cerebrovascular diseases comprising one or more selected from the group consisting of mesenchymal stem cells, culture supernatant of mesenchymal stem cells, and cellular secretions of mesenchymal stem cells.

Disclosed are an Apelin-13 polypeptide mutant, a pharmaceutical composition containing the Apelin-13 polypeptide mutant, and the use thereof.

The invention relates to an engineered exosome for local fat reduction and a preparation method thereof, and belongs to the field of biotechnology and medical beauty. Three fusion proteins, namely an Apelin-first scaffold protein, an NRG4-second scaffold protein and an FLRG-third scaffold protein, are simultaneously displayed on a membrane of the engineered exosome. The preparation method comprises the following steps: constructing a nucleic acid sequence for coding the three fusion proteins, cloning the nucleic acid sequence to an expression vector, introducing the expression vector into a mammal host cell, culturing, and separating and purifying from a cell supernatant to obtain the target exosome. The exosome can be further mixed with locally medicinal or cosmetically acceptable auxiliary materials to prepare local fat-reducing compositions such as gel, cream or essence. Three active proteins with complementary functions are synergistically delivered through a single exosome, glucose and lipid metabolism can be regulated and controlled in a multi-channel mode, muscles are maintained, the composition can act on subcutaneous adipose tissue after being smeared, and the fat reducing effect is achieved.

Disclosed are an Apelin-13 polypeptide mutant, a pharmaceutical composition comprising the Apelin-13 polypeptide mutant, and a use thereof.

Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8-targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.